Global Pneumonia Diagnostic research

Pneumonia Diagnostic Comprehensive Study by Type (Streptococcus-based, Legionella-based, Chlamydophila-based, Viral Pneumonia-based, Mycoplasma Pneumonia-based), Application (Hospitals, Commercial/Private Labs, Physician Offices, Public Health Labs), Pneumonia (Bacterial pneumonia, Viral pneumonia, Fungal type, Mycoplasma pneumonia, Other pneumonias), Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Immunofluorescence, Western Blot, Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Other Technology), End User (Analyzers, Consumables, Researchers), Treatment (Point-Of-Care (POC) Testing, Immunodiagnostics, Molecular Diagnostics, Radiology, Microbiological tests, Radio-graphical studies) Players and Region - Global Market Outlook to 2024

Pneumonia Diagnostic Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Pneumonia is an infectious disease caused by various mediators like bacteria, virus or fungal infections in the lungs. In this disease, there is inflammation of lungs due to the filling of alveoli sacs with fluid (alveoli sacs are the basic and functional unit of lungs). The diagnosis of pneumonia depends on the type of pneumonia occurred and depending on severity. The diagnostic test done mainly by using different technologies. Diagnostic methods are an essential part of the treatment as the direction of treatment is decided by the diagnostic results. Pneumonia is one of the major infectious diseases responsible for significant Deaths and mortality throughout the world.This growth is primarily driven by Increasing No Of Patients Related to Pneumonia .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitN
Value UnitUSD (Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Facilities sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Abbott Laboratories (United States), Enzo Biochem (United States), Beckman Coulter/Danaher (United States), Becton Dickinson (United States), BioMerieux (France), Bio-Rad (United States), Cepheid (United States), Diamedix (United States), DiaSorin (Italy) and Eiken Chemical (Japan), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In October 2019 Siemens Healthineer AG completed the acquisition 100% of Corindus vascular robotics. Prior to the closing of the acquisition, Corindus held a shareholders’ meeting on October 25, 2019, at which 87.5 percent of their stockholders approved the acquisition. The relevant governmental authorities previously granted the approvals required to complete the acquisition.
In November 2018 BioMerieux announced that food and drug administration clearance BIOFIRE FILMARRAY Pneumonia Panel and the CE mark of the Biofire Filmarray Pnuemonial panel plus. The BIOFIRE FILMARRAY Pneumonia Panels aid in the diagnosis of lower respiratory tract infections.The changing lifestyle, as well as sudden changes in climates, is the reason for spreading infectious diseases which may spread pneumonia. Effective diagnostic kits for such infectious diseases are important for deciding the direction for treatment and speedy recovery. The companies, therefore, are relying more on technological benefits and accurate results in their product. Also they keeping the option of merger and acquisition to earn more profit and to catch the market and lead the market for a long period.

Regulatory Insights:
FDA regulates devices, including in vitro diagnostic devices (IVDs), by classifying devices based on the degree of regulation necessary to provide a reasonable assurance of their safety and effectiveness.

Influencing Trend:
Method of Chest Radiography And High-Resolution Computed Tomography(HRCT) are Highly Recommended

Market Growth Drivers:
Increasing No Of Patients Related to Pneumonia and Growing No Of Cases In Under-Developed Countries

Challenges:
Differentiating Viruses Is Becoming Difficult Due To New Emerging Viruses and Changing in Lifestyle Causing Viral

Restraints:
Low Accuracy Of Tests and Ignored Silent Pneumonia (Walking Pneumonia) During Test

Opportunities:
Different Organisations Taking Initiative To Prevent Pneumonia and WHO Initiated Global Action Plan For The Prevention And Control Of Pneumonia (GAPP)

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Pneumonia Diagnostic Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Pneumonia Diagnostic Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Pneumonia Diagnostic players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Pneumonia Diagnostic Study Sheds Light on
— The Pneumonia Diagnostic Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Pneumonia Diagnostic industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Pneumonia Diagnostic industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Streptococcus-based
  • Legionella-based
  • Chlamydophila-based
  • Viral Pneumonia-based
  • Mycoplasma Pneumonia-based
By Application
  • Hospitals
  • Commercial/Private Labs
  • Physician Offices
  • Public Health Labs
By Pneumonia
  • Bacterial pneumonia
  • Viral pneumonia
  • Fungal type
  • Mycoplasma pneumonia
  • Other pneumonias

By Technology
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Immunofluorescence
  • Western Blot
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Other Technology

By End User
  • Analyzers
  • Consumables
  • Researchers

By Treatment
  • Point-Of-Care (POC) Testing
  • Immunodiagnostics
  • Molecular Diagnostics
  • Radiology
  • Microbiological tests
  • Radio-graphical studies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing No Of Patients Related to Pneumonia
      • 3.2.2. Growing No Of Cases In Under-Developed Countries
    • 3.3. Market Challenges
      • 3.3.1. Differentiating Viruses Is Becoming Difficult Due To New Emerging Viruses
      • 3.3.2. Changing in Lifestyle Causing Viral
    • 3.4. Market Trends
      • 3.4.1. Method of Chest Radiography And High-Resolution Computed Tomography(HRCT) are Highly Recommended
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pneumonia Diagnostic, by Type, Application, Pneumonia, Technology, End User, Treatment and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Pneumonia Diagnostic (Value)
      • 5.2.1. Global Pneumonia Diagnostic by: Type (Value)
        • 5.2.1.1. Streptococcus-based
        • 5.2.1.2. Legionella-based
        • 5.2.1.3. Chlamydophila-based
        • 5.2.1.4. Viral Pneumonia-based
        • 5.2.1.5. Mycoplasma Pneumonia-based
      • 5.2.2. Global Pneumonia Diagnostic by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Commercial/Private Labs
        • 5.2.2.3. Physician Offices
        • 5.2.2.4. Public Health Labs
      • 5.2.3. Global Pneumonia Diagnostic by: Pneumonia (Value)
        • 5.2.3.1. Bacterial pneumonia
        • 5.2.3.2. Viral pneumonia
        • 5.2.3.3. Fungal type
        • 5.2.3.4. Mycoplasma pneumonia
        • 5.2.3.5. Other pneumonias
      • 5.2.4. Global Pneumonia Diagnostic by: Technology (Value)
        • 5.2.4.1. Enzyme-Linked Immunosorbent Assay (ELISA)
        • 5.2.4.2. Immunofluorescence
        • 5.2.4.3. Western Blot
        • 5.2.4.4. Polymerase Chain Reaction (PCR)
        • 5.2.4.5. Immunohistochemistry (IHC)
        • 5.2.4.6. Other Technology
      • 5.2.5. Global Pneumonia Diagnostic by: End User (Value)
        • 5.2.5.1. Analyzers
        • 5.2.5.2. Consumables
        • 5.2.5.3. Researchers
      • 5.2.6. Global Pneumonia Diagnostic Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Pneumonia Diagnostic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Enzo Biochem (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Beckman Coulter/Danaher (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Becton Dickinson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BioMerieux (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cepheid (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Diamedix (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DiaSorin (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Eiken Chemical (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Pneumonia Diagnostic Sale, by Type, Application, Pneumonia, Technology, End User, Treatment and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Pneumonia Diagnostic (Value)
      • 7.2.1. Global Pneumonia Diagnostic by: Type (Value)
        • 7.2.1.1. Streptococcus-based
        • 7.2.1.2. Legionella-based
        • 7.2.1.3. Chlamydophila-based
        • 7.2.1.4. Viral Pneumonia-based
        • 7.2.1.5. Mycoplasma Pneumonia-based
      • 7.2.2. Global Pneumonia Diagnostic by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Commercial/Private Labs
        • 7.2.2.3. Physician Offices
        • 7.2.2.4. Public Health Labs
      • 7.2.3. Global Pneumonia Diagnostic by: Pneumonia (Value)
        • 7.2.3.1. Bacterial pneumonia
        • 7.2.3.2. Viral pneumonia
        • 7.2.3.3. Fungal type
        • 7.2.3.4. Mycoplasma pneumonia
        • 7.2.3.5. Other pneumonias
      • 7.2.4. Global Pneumonia Diagnostic by: Technology (Value)
        • 7.2.4.1. Enzyme-Linked Immunosorbent Assay (ELISA)
        • 7.2.4.2. Immunofluorescence
        • 7.2.4.3. Western Blot
        • 7.2.4.4. Polymerase Chain Reaction (PCR)
        • 7.2.4.5. Immunohistochemistry (IHC)
        • 7.2.4.6. Other Technology
      • 7.2.5. Global Pneumonia Diagnostic by: End User (Value)
        • 7.2.5.1. Analyzers
        • 7.2.5.2. Consumables
        • 7.2.5.3. Researchers
      • 7.2.6. Global Pneumonia Diagnostic Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pneumonia Diagnostic: by Type(USD Million)
  • Table 2. Pneumonia Diagnostic Streptococcus-based , by Region USD Million (2016-2021)
  • Table 3. Pneumonia Diagnostic Legionella-based , by Region USD Million (2016-2021)
  • Table 4. Pneumonia Diagnostic Chlamydophila-based , by Region USD Million (2016-2021)
  • Table 5. Pneumonia Diagnostic Viral Pneumonia-based , by Region USD Million (2016-2021)
  • Table 6. Pneumonia Diagnostic Mycoplasma Pneumonia-based , by Region USD Million (2016-2021)
  • Table 7. Pneumonia Diagnostic: by Application(USD Million)
  • Table 8. Pneumonia Diagnostic Hospitals , by Region USD Million (2016-2021)
  • Table 9. Pneumonia Diagnostic Commercial/Private Labs , by Region USD Million (2016-2021)
  • Table 10. Pneumonia Diagnostic Physician Offices , by Region USD Million (2016-2021)
  • Table 11. Pneumonia Diagnostic Public Health Labs , by Region USD Million (2016-2021)
  • Table 12. Pneumonia Diagnostic: by Pneumonia(USD Million)
  • Table 13. Pneumonia Diagnostic Bacterial pneumonia , by Region USD Million (2016-2021)
  • Table 14. Pneumonia Diagnostic Viral pneumonia , by Region USD Million (2016-2021)
  • Table 15. Pneumonia Diagnostic Fungal type , by Region USD Million (2016-2021)
  • Table 16. Pneumonia Diagnostic Mycoplasma pneumonia , by Region USD Million (2016-2021)
  • Table 17. Pneumonia Diagnostic Other pneumonias , by Region USD Million (2016-2021)
  • Table 18. Pneumonia Diagnostic: by Technology(USD Million)
  • Table 19. Pneumonia Diagnostic Enzyme-Linked Immunosorbent Assay (ELISA) , by Region USD Million (2016-2021)
  • Table 20. Pneumonia Diagnostic Immunofluorescence , by Region USD Million (2016-2021)
  • Table 21. Pneumonia Diagnostic Western Blot , by Region USD Million (2016-2021)
  • Table 22. Pneumonia Diagnostic Polymerase Chain Reaction (PCR) , by Region USD Million (2016-2021)
  • Table 23. Pneumonia Diagnostic Immunohistochemistry (IHC) , by Region USD Million (2016-2021)
  • Table 24. Pneumonia Diagnostic Other Technology , by Region USD Million (2016-2021)
  • Table 25. Pneumonia Diagnostic: by End User(USD Million)
  • Table 26. Pneumonia Diagnostic Analyzers , by Region USD Million (2016-2021)
  • Table 27. Pneumonia Diagnostic Consumables , by Region USD Million (2016-2021)
  • Table 28. Pneumonia Diagnostic Researchers , by Region USD Million (2016-2021)
  • Table 29. South America Pneumonia Diagnostic, by Country USD Million (2016-2021)
  • Table 30. South America Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 31. South America Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 32. South America Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 33. South America Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 34. South America Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 35. South America Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 36. Brazil Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 37. Brazil Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 38. Brazil Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 39. Brazil Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 40. Brazil Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 41. Brazil Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 42. Argentina Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 43. Argentina Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 44. Argentina Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 45. Argentina Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 46. Argentina Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 47. Argentina Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 48. Rest of South America Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 49. Rest of South America Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 50. Rest of South America Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 51. Rest of South America Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 52. Rest of South America Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 53. Rest of South America Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 54. Asia Pacific Pneumonia Diagnostic, by Country USD Million (2016-2021)
  • Table 55. Asia Pacific Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 56. Asia Pacific Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 57. Asia Pacific Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 58. Asia Pacific Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 59. Asia Pacific Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 60. Asia Pacific Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 61. China Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 62. China Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 63. China Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 64. China Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 65. China Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 66. China Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 67. Japan Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 68. Japan Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 69. Japan Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 70. Japan Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 71. Japan Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 72. Japan Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 73. India Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 74. India Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 75. India Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 76. India Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 77. India Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 78. India Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 79. South Korea Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 80. South Korea Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 81. South Korea Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 82. South Korea Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 83. South Korea Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 84. South Korea Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 85. Taiwan Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 86. Taiwan Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 87. Taiwan Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 88. Taiwan Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 89. Taiwan Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 90. Taiwan Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 91. Australia Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 92. Australia Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 93. Australia Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 94. Australia Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 95. Australia Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 96. Australia Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 97. Rest of Asia-Pacific Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 98. Rest of Asia-Pacific Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 99. Rest of Asia-Pacific Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 100. Rest of Asia-Pacific Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 101. Rest of Asia-Pacific Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 102. Rest of Asia-Pacific Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 103. Europe Pneumonia Diagnostic, by Country USD Million (2016-2021)
  • Table 104. Europe Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 105. Europe Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 106. Europe Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 107. Europe Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 108. Europe Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 109. Europe Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 110. Germany Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 111. Germany Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 112. Germany Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 113. Germany Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 114. Germany Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 115. Germany Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 116. France Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 117. France Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 118. France Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 119. France Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 120. France Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 121. France Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 122. Italy Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 123. Italy Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 124. Italy Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 125. Italy Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 126. Italy Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 127. Italy Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 128. United Kingdom Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 129. United Kingdom Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 130. United Kingdom Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 131. United Kingdom Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 132. United Kingdom Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 133. United Kingdom Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 134. Netherlands Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 135. Netherlands Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 136. Netherlands Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 137. Netherlands Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 138. Netherlands Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 139. Netherlands Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 140. Rest of Europe Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 141. Rest of Europe Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 142. Rest of Europe Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 143. Rest of Europe Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 144. Rest of Europe Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 145. Rest of Europe Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 146. MEA Pneumonia Diagnostic, by Country USD Million (2016-2021)
  • Table 147. MEA Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 148. MEA Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 149. MEA Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 150. MEA Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 151. MEA Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 152. MEA Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 153. Middle East Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 154. Middle East Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 155. Middle East Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 156. Middle East Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 157. Middle East Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 158. Middle East Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 159. Africa Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 160. Africa Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 161. Africa Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 162. Africa Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 163. Africa Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 164. Africa Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 165. North America Pneumonia Diagnostic, by Country USD Million (2016-2021)
  • Table 166. North America Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 167. North America Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 168. North America Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 169. North America Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 170. North America Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 171. North America Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 172. United States Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 173. United States Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 174. United States Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 175. United States Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 176. United States Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 177. United States Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 178. Canada Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 179. Canada Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 180. Canada Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 181. Canada Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 182. Canada Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 183. Canada Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 184. Mexico Pneumonia Diagnostic, by Type USD Million (2016-2021)
  • Table 185. Mexico Pneumonia Diagnostic, by Application USD Million (2016-2021)
  • Table 186. Mexico Pneumonia Diagnostic, by Pneumonia USD Million (2016-2021)
  • Table 187. Mexico Pneumonia Diagnostic, by Technology USD Million (2016-2021)
  • Table 188. Mexico Pneumonia Diagnostic, by End User USD Million (2016-2021)
  • Table 189. Mexico Pneumonia Diagnostic, by Treatment USD Million (2016-2021)
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Pneumonia Diagnostic: by Type(USD Million)
  • Table 201. Pneumonia Diagnostic Streptococcus-based , by Region USD Million (2022-2027)
  • Table 202. Pneumonia Diagnostic Legionella-based , by Region USD Million (2022-2027)
  • Table 203. Pneumonia Diagnostic Chlamydophila-based , by Region USD Million (2022-2027)
  • Table 204. Pneumonia Diagnostic Viral Pneumonia-based , by Region USD Million (2022-2027)
  • Table 205. Pneumonia Diagnostic Mycoplasma Pneumonia-based , by Region USD Million (2022-2027)
  • Table 206. Pneumonia Diagnostic: by Application(USD Million)
  • Table 207. Pneumonia Diagnostic Hospitals , by Region USD Million (2022-2027)
  • Table 208. Pneumonia Diagnostic Commercial/Private Labs , by Region USD Million (2022-2027)
  • Table 209. Pneumonia Diagnostic Physician Offices , by Region USD Million (2022-2027)
  • Table 210. Pneumonia Diagnostic Public Health Labs , by Region USD Million (2022-2027)
  • Table 211. Pneumonia Diagnostic: by Pneumonia(USD Million)
  • Table 212. Pneumonia Diagnostic Bacterial pneumonia , by Region USD Million (2022-2027)
  • Table 213. Pneumonia Diagnostic Viral pneumonia , by Region USD Million (2022-2027)
  • Table 214. Pneumonia Diagnostic Fungal type , by Region USD Million (2022-2027)
  • Table 215. Pneumonia Diagnostic Mycoplasma pneumonia , by Region USD Million (2022-2027)
  • Table 216. Pneumonia Diagnostic Other pneumonias , by Region USD Million (2022-2027)
  • Table 217. Pneumonia Diagnostic: by Technology(USD Million)
  • Table 218. Pneumonia Diagnostic Enzyme-Linked Immunosorbent Assay (ELISA) , by Region USD Million (2022-2027)
  • Table 219. Pneumonia Diagnostic Immunofluorescence , by Region USD Million (2022-2027)
  • Table 220. Pneumonia Diagnostic Western Blot , by Region USD Million (2022-2027)
  • Table 221. Pneumonia Diagnostic Polymerase Chain Reaction (PCR) , by Region USD Million (2022-2027)
  • Table 222. Pneumonia Diagnostic Immunohistochemistry (IHC) , by Region USD Million (2022-2027)
  • Table 223. Pneumonia Diagnostic Other Technology , by Region USD Million (2022-2027)
  • Table 224. Pneumonia Diagnostic: by End User(USD Million)
  • Table 225. Pneumonia Diagnostic Analyzers , by Region USD Million (2022-2027)
  • Table 226. Pneumonia Diagnostic Consumables , by Region USD Million (2022-2027)
  • Table 227. Pneumonia Diagnostic Researchers , by Region USD Million (2022-2027)
  • Table 228. South America Pneumonia Diagnostic, by Country USD Million (2022-2027)
  • Table 229. South America Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 230. South America Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 231. South America Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 232. South America Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 233. South America Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 234. South America Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 235. Brazil Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 236. Brazil Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 237. Brazil Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 238. Brazil Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 239. Brazil Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 240. Brazil Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 241. Argentina Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 242. Argentina Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 243. Argentina Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 244. Argentina Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 245. Argentina Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 246. Argentina Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 247. Rest of South America Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 248. Rest of South America Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 249. Rest of South America Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 250. Rest of South America Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 251. Rest of South America Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 252. Rest of South America Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 253. Asia Pacific Pneumonia Diagnostic, by Country USD Million (2022-2027)
  • Table 254. Asia Pacific Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 255. Asia Pacific Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 256. Asia Pacific Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 257. Asia Pacific Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 258. Asia Pacific Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 259. Asia Pacific Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 260. China Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 261. China Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 262. China Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 263. China Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 264. China Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 265. China Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 266. Japan Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 267. Japan Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 268. Japan Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 269. Japan Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 270. Japan Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 271. Japan Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 272. India Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 273. India Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 274. India Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 275. India Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 276. India Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 277. India Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 278. South Korea Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 279. South Korea Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 280. South Korea Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 281. South Korea Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 282. South Korea Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 283. South Korea Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 284. Taiwan Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 285. Taiwan Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 286. Taiwan Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 287. Taiwan Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 288. Taiwan Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 289. Taiwan Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 290. Australia Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 291. Australia Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 292. Australia Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 293. Australia Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 294. Australia Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 295. Australia Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 296. Rest of Asia-Pacific Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 297. Rest of Asia-Pacific Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 298. Rest of Asia-Pacific Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 299. Rest of Asia-Pacific Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 300. Rest of Asia-Pacific Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 301. Rest of Asia-Pacific Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 302. Europe Pneumonia Diagnostic, by Country USD Million (2022-2027)
  • Table 303. Europe Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 304. Europe Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 305. Europe Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 306. Europe Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 307. Europe Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 308. Europe Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 309. Germany Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 310. Germany Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 311. Germany Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 312. Germany Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 313. Germany Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 314. Germany Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 315. France Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 316. France Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 317. France Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 318. France Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 319. France Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 320. France Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 321. Italy Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 322. Italy Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 323. Italy Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 324. Italy Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 325. Italy Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 326. Italy Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 327. United Kingdom Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 328. United Kingdom Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 329. United Kingdom Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 330. United Kingdom Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 331. United Kingdom Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 332. United Kingdom Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 333. Netherlands Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 334. Netherlands Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 335. Netherlands Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 336. Netherlands Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 337. Netherlands Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 338. Netherlands Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 339. Rest of Europe Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 340. Rest of Europe Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 341. Rest of Europe Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 342. Rest of Europe Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 343. Rest of Europe Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 344. Rest of Europe Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 345. MEA Pneumonia Diagnostic, by Country USD Million (2022-2027)
  • Table 346. MEA Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 347. MEA Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 348. MEA Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 349. MEA Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 350. MEA Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 351. MEA Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 352. Middle East Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 353. Middle East Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 354. Middle East Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 355. Middle East Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 356. Middle East Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 357. Middle East Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 358. Africa Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 359. Africa Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 360. Africa Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 361. Africa Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 362. Africa Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 363. Africa Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 364. North America Pneumonia Diagnostic, by Country USD Million (2022-2027)
  • Table 365. North America Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 366. North America Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 367. North America Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 368. North America Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 369. North America Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 370. North America Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 371. United States Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 372. United States Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 373. United States Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 374. United States Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 375. United States Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 376. United States Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 377. Canada Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 378. Canada Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 379. Canada Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 380. Canada Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 381. Canada Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 382. Canada Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 383. Mexico Pneumonia Diagnostic, by Type USD Million (2022-2027)
  • Table 384. Mexico Pneumonia Diagnostic, by Application USD Million (2022-2027)
  • Table 385. Mexico Pneumonia Diagnostic, by Pneumonia USD Million (2022-2027)
  • Table 386. Mexico Pneumonia Diagnostic, by Technology USD Million (2022-2027)
  • Table 387. Mexico Pneumonia Diagnostic, by End User USD Million (2022-2027)
  • Table 388. Mexico Pneumonia Diagnostic, by Treatment USD Million (2022-2027)
  • Table 389. Research Programs/Design for This Report
  • Table 390. Key Data Information from Secondary Sources
  • Table 391. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pneumonia Diagnostic: by Type USD Million (2016-2021)
  • Figure 5. Global Pneumonia Diagnostic: by Application USD Million (2016-2021)
  • Figure 6. Global Pneumonia Diagnostic: by Pneumonia USD Million (2016-2021)
  • Figure 7. Global Pneumonia Diagnostic: by Technology USD Million (2016-2021)
  • Figure 8. Global Pneumonia Diagnostic: by End User USD Million (2016-2021)
  • Figure 9. South America Pneumonia Diagnostic Share (%), by Country
  • Figure 10. Asia Pacific Pneumonia Diagnostic Share (%), by Country
  • Figure 11. Europe Pneumonia Diagnostic Share (%), by Country
  • Figure 12. MEA Pneumonia Diagnostic Share (%), by Country
  • Figure 13. North America Pneumonia Diagnostic Share (%), by Country
  • Figure 14. Global Pneumonia Diagnostic share by Players 2021 (%)
  • Figure 15. Global Pneumonia Diagnostic share by Players (Top 3) 2021(%)
  • Figure 16. Global Pneumonia Diagnostic share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 20. Enzo Biochem (United States) Revenue, Net Income and Gross profit
  • Figure 21. Enzo Biochem (United States) Revenue: by Geography 2021
  • Figure 22. Beckman Coulter/Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 23. Beckman Coulter/Danaher (United States) Revenue: by Geography 2021
  • Figure 24. Becton Dickinson (United States) Revenue, Net Income and Gross profit
  • Figure 25. Becton Dickinson (United States) Revenue: by Geography 2021
  • Figure 26. BioMerieux (France) Revenue, Net Income and Gross profit
  • Figure 27. BioMerieux (France) Revenue: by Geography 2021
  • Figure 28. Bio-Rad (United States) Revenue, Net Income and Gross profit
  • Figure 29. Bio-Rad (United States) Revenue: by Geography 2021
  • Figure 30. Cepheid (United States) Revenue, Net Income and Gross profit
  • Figure 31. Cepheid (United States) Revenue: by Geography 2021
  • Figure 32. Diamedix (United States) Revenue, Net Income and Gross profit
  • Figure 33. Diamedix (United States) Revenue: by Geography 2021
  • Figure 34. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 35. DiaSorin (Italy) Revenue: by Geography 2021
  • Figure 36. Eiken Chemical (Japan) Revenue, Net Income and Gross profit
  • Figure 37. Eiken Chemical (Japan) Revenue: by Geography 2021
  • Figure 38. Global Pneumonia Diagnostic: by Type USD Million (2022-2027)
  • Figure 39. Global Pneumonia Diagnostic: by Application USD Million (2022-2027)
  • Figure 40. Global Pneumonia Diagnostic: by Pneumonia USD Million (2022-2027)
  • Figure 41. Global Pneumonia Diagnostic: by Technology USD Million (2022-2027)
  • Figure 42. Global Pneumonia Diagnostic: by End User USD Million (2022-2027)
  • Figure 43. South America Pneumonia Diagnostic Share (%), by Country
  • Figure 44. Asia Pacific Pneumonia Diagnostic Share (%), by Country
  • Figure 45. Europe Pneumonia Diagnostic Share (%), by Country
  • Figure 46. MEA Pneumonia Diagnostic Share (%), by Country
  • Figure 47. North America Pneumonia Diagnostic Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories (United States)
  • Enzo Biochem (United States)
  • Beckman Coulter/Danaher (United States)
  • Becton Dickinson (United States)
  • BioMerieux (France)
  • Bio-Rad (United States)
  • Cepheid (United States)
  • Diamedix (United States)
  • DiaSorin (Italy)
  • Eiken Chemical (Japan)
Additional players considered in the study are as follows:
Elitech Group (France) , Enzo Biochem (United States) , Fujirebio (Japan) , Grifols (Spain) , GlaxoSmithKline (United Kingdom) , Hologic (United States) , Leica Biosystems (Germany) , Lonza (Switzerland) , Siemens Healthineers (Germany) , Takara Bio (Japan) , Thermo Fisher (United States)
Select User Access Type

Key Highlights of Report


Feb 2020 230 Pages 63 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pneumonia Diagnostic research Quantitative research analysis
Global Pneumonia Diagnostic research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Pneumonia Diagnostic Market are Abbott Laboratories (United States), Enzo Biochem (United States), Beckman Coulter/Danaher (United States), Becton Dickinson (United States), BioMerieux (France), Bio-Rad (United States), Cepheid (United States), Diamedix (United States), DiaSorin (Italy) and Eiken Chemical (Japan) etc.
Hospitals segment in Global market to hold robust market share owing to "Increasing No Of Patients Related to Pneumonia ".

Know More About Global Pneumonia Diagnostic research Report?

Have a Query? Click Here

Other Related Reports

Bedsore Cushion Comprehensive Study by Type (Rubber Cushion, PVC Cushion), Application (Hospital, Residential, Others), Distribution Channel (Online, Offline) Players and Region - Global Market Outlo...
$ 3500
Pneumonia Testing Comprehensive Study by Application (Hospitals, Diagnostic Laboratories, Homecare, Others), Technology (Enzyme Linked Immunosorbent Assay, Immunofluorescence, Western Blot, Polymeras...
$ 3750
Animal Healthcare Comprehensive Study by Type (Vaccines, Anti-Bacterial / Antibiotic, Anti-Chronic Respiratory Disease, Anticoccidials, Antihelmintics, Disinfectant, Enzymes, Fly Binder / Control, Gu...
$ 3750
Latex Allergy Comprehensive Study by Type (IgE-mediated allergic reaction (Type I), Allergic contact dermatitis (Type IV), Irritant contact dermatitis), Application (Healthcare workers, Rubber indust...
$ 3750
Maternal Health Comprehensive Study by Type (Hormones, Nutritive, Analgesics, Anti-Infectives, Others), Application (General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Energy & W...
$ 3650
Metabolic Cart Comprehensive Study by Type (The Breath-By-Breath System, The Mixing Chamber System), Application (Hospital, Private Clinic, Nursing Home, Others), Product (Desktop Device Type, Ground...
$ 3500